Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Almaral is a venture capital firm established in 2022, headquartered in Helsinki, Finland. The firm specializes in the biotechnology and life sciences sectors, focusing on early-stage investments across Europe. Almaral aims to support innovative and growth-oriented companies by providing not only capital but also extensive operational assistance.
Currently, Almaral manages a portfolio that includes five notable biotech companies. The firm emphasizes a hands-on approach, offering business and marketing consulting, legal services, and operational support to ensure that its portfolio companies have the necessary resources to thrive. Almaral's commitment to responsible investing aligns with its adherence to Environmental, Social, and Governance (ESG) principles.
Almaral invests in early-stage biotechnology and life sciences startups located in Europe. The firm typically provides funding ranging from €0.5 million to €1 million. Almaral seeks companies with strong, execution-capable teams and expects to take a board position as part of its investment criteria. The firm emphasizes responsible investing and adherence to Environmental, Social, and Governance (ESG) principles, ensuring that its portfolio aligns with sustainable practices.
Investment stages include pre-seed, seed, seed+ (extension), and Series A. Almaral's focus on the biotech sector encompasses a range of areas, including medical devices and diagnostics. The firm positions itself as a hybrid venture studio, addressing the gap in early-stage capital in European biotech by providing comprehensive operational support alongside funding.
Almaral has built a diverse portfolio of innovative companies in the biotechnology sector, including:
These companies represent Almaral's commitment to supporting growth-oriented startups in the biotech field, with a focus on innovative solutions that address critical healthcare challenges.
Dr. Maria Severina: Investment Partner and CEO. Dr. Severina holds a Ph.D. in immunochemistry and is the founder of HyTest, a Finnish diagnostics company.
Mr. Alex Michine: Investment Partner and Chairman of the Board. Mr. Michine has over 25 years of experience in life sciences and holds an M.Sc. and an MBA.
Dr. Kalevi Kurkijärvi: Partner with a Ph.D. in Biochemistry and 40 years of industry experience.
Elina Makino: Scientific Advisor and Partner, with a Ph.D. and over 20 years of experience in pharma and biotech.
Mr. Juuso Enala: Partner with 30 years of experience in marketing communications.
Mr. Pekka Hildén: Partner with an M.Sc. in Biochemistry and an MBA, specializing in IVD and medical devices.
To pitch Almaral, founders should use the submission form available on their website. The pitch deck should include a clear overview of the business model, market opportunity, and team qualifications. Almaral prefers concise presentations that highlight key metrics and milestones.
Response times may vary, but founders can expect feedback within a few weeks. Warm introductions are beneficial but not mandatory. Almaral encourages direct communication and values transparency in all interactions.
Almaral has been actively participating in industry events, including the upcoming Investor Meetup at Terkko Health Hub scheduled for April 10, 2025, and the LSX Nordic Congress, which focuses on partnering, strategy, and investment in the Nordic and Baltic life sciences sectors.
Recent developments in Almaral's portfolio include Marginum's technology being validated in brain tumor surgery trials, showcasing the firm's commitment to supporting innovative solutions in healthcare.
What are Almaral's investment criteria?
Almaral focuses exclusively on early-stage biotechnology and life sciences startups in Europe. The firm looks for experienced teams capable of executing their business plans and requires a board position as part of its investment criteria. ESG compliance is also a prerequisite for investment.
How can I pitch to Almaral?
Interested founders should submit their proposals through the submission form available on Almaral's website. General inquiries can be directed to info@almaral.eu. The firm values clear communication and expects detailed business plans that outline the startup's vision and execution strategy.
What makes Almaral different from other VC firms?
Almaral distinguishes itself by providing not only funding but also comprehensive operational support, including business consulting, legal services, and assistance with commercialization. This hybrid venture studio model allows Almaral to address the unique challenges faced by biotech startups.
What is the typical check size for investments?
Almaral typically invests between €0.5 million and €1 million in its portfolio companies. This range allows the firm to support startups at various stages of their development.
What sectors does Almaral focus on?
The firm primarily invests in the biotechnology and life sciences sectors, including medical devices and diagnostics. Almaral aims to support innovative companies that are addressing significant healthcare challenges.
What kind of support can portfolio companies expect?
Almaral provides extensive support to its portfolio companies, including business and marketing consulting, legal services, risk management, strategic planning, and assistance with early-stage sales and marketing. This comprehensive approach helps startups navigate the complexities of the biotech industry.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.